Prolongation of concordant xenograft survival by a newly developed drug, FTY720.
Fujiwara
I
I
Second Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Nakajima
H
H
Matsuda
T
T
Mizuta
N
N
Yamagishi
H
H
Oka
T
T
D000818:Animals; D000910:Antibodies, Heterophile / Q000097:blood; D003131:Combined Modality Therapy; D006224:Cricetinae; D000068876:Fingolimod Hydrochloride; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D006146:Guanidines / Q000627:therapeutic use; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007959:Lymphocyte Culture Test, Mixed; D011409:Propylene Glycols / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D013110:Sphingosine / Q000031:analogs & derivatives; D013154:Spleen / Q000276:immunology; D013156:Splenectomy; D014183:Transplantation, Heterologous / Q000276:immunology* / Q000473:pathology
D000910:Antibodies, Heterophile; D006146:Guanidines; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; C037258:gusperimus